https://orcid.org/0000-0003-2993-5478
ResearcherID: A-7283-2008
Scopus Author ID: 7405842809
Medico Especialista Microbiología vinculado Servicio de Microbiología Hospital Universitario Miguel Servet. Director Grupo de Investigación de Genética de Micobacterias perteneciente al IIS Aragón y CIBERES.
Previous experimental Work: After ending my studies in Medicine in 1982, I focused my research in the understanding of the mechanisms of resistance in bacteria in the Department of Microbiology of University of Zaragoza under the direction of Professor Gomez-Lus. My postdoctoral studies were focused on the dissemination of antibiotic resistance genes by transposition between the chromosomes and plasmids in bacteria in the Department of Biochemistry and Molecular Biology, University of Cantabria under the Direction of Professor Juanma García-Lobo and Professor Fernando de la Cruz. In 1987, I came to Pasteur Institute in Paris, where I worked in the Unité de Génie Microbiologique (directed by Professor Julian Davies) and under the direct supervision of Professor Brigitte Gicquel specializing in Bacterial Genetics and Molecular Biology of Mycobacteria focusing in the study of the mechanisms of resistance in Mycobacteria and the mechanisms of pathogenicity of M. tuberculosis.
Present work: Our team aims to develop novel TB vaccines and vaccination strategies to improve protection against pulmonary TB: Since 2005 I am a full Professor of Microbiology at the Faculty of Medicine at University of Zaragoza and I am member of the Advisory Committee of Tuberculosis Vaccine Initiative (TBVI), with more than 30 years of experience in mycobacterial genetics. Our research group currently works in collaborative TB research projects together with research groups of Europe, Africa and America. Our research has been continuously funded by National and European Union Research Programs TB research since 1992. Our research group belongs to CIBERES, a research network on respiratory diseases of the Spanish Ministry of Health (Instituto de Salud Carlos III). I have published 182 articles that have been cited more than 10,100 times with a h-index of 44. I am co-inventor of several patents on "tuberculosis vaccine" owned by the University of Zaragoza, exclusively licensed to Biofabri as industrial partner and clinical developer of MTBVAC.
Member of National Committees:
working group to prepare the consensus document of "multidrug-resistant TB " of the European Academy of Sciences
Advisory Council of Research and Development of the Government of Aragon from 2009 to 2014
Research Commission of the University of Zaragoza from 2009 to 2018
Member of International Committees:
Steering Committee European Integrated Project "TB VAC" 2006-2009 FP6
Advisory Committee TBVI, European Initiative TB Vaccine since started in 2007 to date.
Membership of Scientific Societies: Spanish Society of Microbiology, American Society for Microbiology since 1991, International Union Against TB since 1996
Founding member of the TB Network of Latin America and the Caribbean University of the United Nations (1995)
Prizes: Ibercaja Investigación en Biomedicina 1995, Desarrollo Sostenible “Fundación Ecología y Desarrollo” 2006, Diario Médico Mejores Ideas 2006, Aragoneses del año 2010 “Ciencia y Tecnología” al Grupo de Genética de micobacterias, Aragón Investiga del Gobierno de Aragón la Excelencia investigadora 2010. Medalla del Justicia de Aragón 2021.
H-index: 46
Total articles published: 167
Total Times Cited: 10.100
7 Five-year recognized teaching activity (Quinquenios 1983-2018)
6 Six-year recognized research (Sexenios 1985-2021)
16 Thesis supervised
Artículos
- Luabeya, Angelique Kany Kany; Rozot, Virginie; Imbratta, Claire; Ratangee, Frances; Shenje, Justin; Tameris, Michele; Mendelsohn, Simon C; Geldenhuys, Hennie; Fisher, Michelle; Musvosvi, Munyaradzi; Young, Carly; Mulenga, Humphrey; Bilek, Nicole; Mabwe, Simbarashe; Jelsbak, Ingrid Murillo; Rodríguez, Esteban; Puentes, Eugenia; Doce, Juana; Aguilo, Nacho; Martin, Carlos; Pillay, Cadwill; Tait, Dereck; Russell, Marisa; Van Der Merve, Arrie; Rutkowski, Kathryn; Hunt, Devin; Ginsberg, Ann; Scriba, Thomas J; Hatherill, Mark; Swanepoel, Liticia; Davids, Ilse; de Kock, Marwou; Botes, Natasja; Rossouw, Susan; Barnard, Liezl; Verster, Elmien; Veldsman, Ashley; Meyer, Faheemah; Kaskar, Masooda; Leopeng, Thelma; Noble, Julia; Africa, Hadn; Valley, Habibullah; Steyn, Marcia; Makhete, Lebohgang; Mangali, Sandisiwe; Nkambule, Hlengiwe; Erasmus, Mzwandile; Jaxa, Lungisa; Raphela, Rodney; Schreuder, Constance; Cloete, Yolundi; Nambida, Onke; Companie, Alessandro; Khomba, Gloria; Abrahams, Charmaine; Magawu, Patricia; Mactavie, Lauren; Erasmus, Margareth; Van Rooyen, Johanna; Mouton, Angelique; Opperman, Fajwa; Segelaar, Carmen; Tyambetyu, Petrus; Diamond, Bongani; Veldtsman, Helen; Reid, Tim. Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b–2a, double-blind, dose-escalation, randomised controlled trial. THE LANCET. GLOBAL HEALTH. 2025. DOI: 10.1016/S2214-109X(25)00046-4
- Tameris, Michele; Rozot, Virginie; Imbratta, Claire; Geldenhuys, Hennie; Mendelsohn, Simon C.; Kany Luabeya, Angelique Kany; Shenje, Justin; Tredoux, Nicolette; Fisher, Michelle; Mulenga, Humphrey; Bilek, Nicole; Young, Carly; Veldsman, Ashley; Botes, Natasja; Thole, Jelle; Fritzell, Bernard; Mukherjee, Rajat; Jelsbak, Ingrid Murillo; Rodriguez, Esteban; Puentes, Eugenia; Doce, Juana; Marinova, Dessislava; Gonzalo-Asensio, Jesús; Aguilo, Nacho; Martin, Carlos; Scriba, Thomas J.; Hatherill, Mark; Abrahams, Charmaine; Africa, Hadn; Arendsen, Denis; Barnard, Liezl; Cloete, Yolundi; Davids, Ilse; Erasmus, Mzwandile; Filander, Elizabeth; Gregg, Yolande; Herling, Roxane; Jansen, Ruwiyda; Jack, Lungisa; Kelepu, Xoliswe; Kyepa, Henriette; Leopeng, Thelma; Mabwe, Simbarahse; Mactavie, Lauren; Makhete, Lebohang; Mangali, Sandisiwe; Mouton, Angelique; Nkambule, Hlengiwe; Noble, Julia; Nombida, Onke; Nqakala, Nambitha; Opperman, Fajwa; Raphela, Rodney; Rossouw, Susan; Schoeman, Elisma; Schreuder, Constance; Steyn, Marcia; Swanepoel, Liticia; Toefy, Asma; Tromp, Anele; Tyambethu, Petrus; Valley, Habibullah; Van Rooyes, Johanna. Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting. EBIOMEDICINE. 2025. DOI: 10.1016/j.ebiom.2025.105628
- Felgueres, María-José; Esteso, Gloria; García-Jiménez, Álvaro F.; Benguría, Alberto; Vázquez, Enrique; Aguiló, Nacho; Puentes, Eugenia; Dopazo, Ana; Murillo, Ingrid; Martín, Carlos; Rodríguez, Esteban; Reyburn, Hugh T.; Valés-Gómez, Mar. Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine. NPJ VACCINES. 2025. DOI: 10.1038/s41541-025-01110-3
- Peralta-Álvarez, Marco Polo; Downward, Keya; White, Andrew; Redondo Azema, Hugo; Sibley, Laura; Sarfas, Charlotte; Morrison, Alexandra; Dennis, Mike; Diaz-Santana, Delia; Harris, Stephanie A.; Li, Shuailin; Puentes, Eugenia; Aguilo, Nacho; Martin, Carlos; Sharpe, Sally; Mcshane, Helen; Tanner, Rachel. MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates. NPJ VACCINES. 2024. DOI: 10.1038/s41541-024-01009-5
- Calvo, Silvia; Rodrigo-Muñoz, Jose Manuel; Tarancón, Raquel; Uranga, Santiago; Martín, Carlos; Pozo, Victoria Del; Aguiló, Nacho. Correlation between systemic allergen desensitisation and long-term asthma protection in mice following intravenous administration of the live tuberculosis vaccine MTBVAC. EBIOMEDICINE. 2024. DOI: 10.1016/j.ebiom.2024.105272
- Peralta Alvarez, Marco Polo;Jones, Holly;Redondo Azema, Hugo;Davis, Chloe;White, Andrew D. ;Sarfas, Charlotte;Dennis, Mike;Li,Shuailin;Wright, Daniel;Puentes, Eugenia;Kimuda, Simon;Belij-Rammerstorfer, Sandra;Aguilo, Nacho;Martin, Carlos;Sharpe, Sally;Mcshane, Helen;Tanner,Rachel. Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates. FRONTIERS IN IMMUNOLOGY. 2024. DOI: 10.3389/fimmu.2024.1387454
- Rabodoarivelo, Marie Sylvianne; Gómez, Ana Belén; Picó Marco, Ana; Martín, Carlos; Ramón-García, Santiago. Susceptibility testing of the live attenuated tuberculosis vaccine BCG and the vaccine candidate MTBVAC to currently WHO-recommended anti-tuberculosis drugs by the European committee on antimicrobial susceptibility testing (EUCAST) method. CLINICAL MICROBIOLOGY AND INFECTION. 2024. DOI: 10.1016/j.cmi.2024.04.017
- Esteso, Gloria; Felgueres, María José; García Jiménez, Álvaro F.; Reyburn Valés, Christina; Benguría, Alberto; Vázquez, Enrique; Reyburn, Hugh T.; Aguiló, Nacho; Martín, Carlos; Puentes, Eugenia; Murillo, Ingrid; Rodríguez, Esteban; Valés-Gómez, Mar. BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and ¿d T-cells that can be further expanded in vitro. ONCOIMMUNOLOGY. 2023. DOI: 10.1080/2162402X.2022.2160094
- Malaga, Wladimir; Payros, Delphine; Meunier, Eva; Frigui, Wafa; Sayes, Fadel; Pawlik, Alexandre; Orgeur, Mickael; Berrone, Céline; Moreau, Flavie; Mazères, Serge; Gonzalo-Asensio, Jesus; Rengel, David; Martin, Carlos; Astarie-Dequeker, Catherine; Mourey, Lionel; Brosch, Roland; Guilhot, Christophe. Natural mutations in the sensor kinase of the PhoPR two-component regulatory system modulate virulence of ancestor-like tuberculosis bacilli. PLOS PATHOGENS. 2023. DOI: 10.1371/journal.ppat.1011437
- Moreo, Eduardo; Jarit-Cabanillas, Aitor; Robles-Vera, Iñaki; Uranga, Santiago; Guerrero, Claudia; Gómez, Ana Belén; Mata-Martínez, Pablo; Minute, Luna; Araujo-Voces, Miguel; Felgueres, María José; Esteso, Gloria; Uranga-Murillo, Iratxe; Arias, Maykel; Pardo, Julián; Martín, Carlos; Valés-Gómez, Mar; del Fresno, Carlos; Sancho, David; Aguiló, Nacho. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung. NATURE COMMUNICATIONS. 2023. DOI: 10.1038/s41467-023-41768-8
- Moreno Guillén, Santiago; Rodríguez-Artalejo, Fernando; Ruiz-Galiana, Julián; Cantón, Rafael; de Lucas Ramos, Pilar; García-Botella, Alejandra; García-Lledó, Alberto; Hernández-Sampelayo, Teresa; Gómez-Pavón, Javier; González del Castillo, Juan; Martín-Delgado, Mari Cruz; Martín Sánchez, Francisco Javier; Martínez-Sellés, Manuel; Molero García, José María; Santiago, Begoña; Caminero, José Antonio; Barros, Carlos; García de Viedma, Darío; Martín, Carlos; Bouza, Emilio. Tuberculosis in Spain: an opinion paper. REVISTA ESPAÑOLA DE QUIMIOTERAPIA. 2023. DOI: 10.37201/req/115.2023
- Lacámara, Sergio; Martin, Carlos. MTBVAC: A Tuberculosis Vaccine Candidate Advancing Towards Clinical Efficacy Trials in TB Prevention. ARCHIVOS DE BRONCONEUMOLOGIA. 2023. DOI: 10.1016/j.arbres.2023.09.009
- Martínez-Sellés, Manuel; Martín Sánchez, Francisco Javier; Moreno Guillén, Santiago; Rodríguez-Artalejo, Fernando; Ruiz-Galiana, Julián; Cantón, Rafael; de Lucas Ramos, Pilar; García-Botella, Alejandra; García-Lledó, Alberto; Hernández-Sampelayo, Teresa; Gómez-Pavón, Javier; González del Castillo, Juan; Martín-Delgado, Mari Cruz; Molero García, José María; Santiago, Begoña; Caminero, José Antonio; Barros, Carlos; García de Viedma, Darío; Martín, Carlos; Bouza, Emilio. Advantages and disadvantages of maintaining the mandatory use of masks in health centers and nursing homes in Spain. How and when is it justified to maintain it?. REVISTA ESPAÑOLA DE QUIMIOTERAPIA. 2023. DOI: 10.37201/req/070.2023
- Pérez, Irene; Campos-Pardos, Elena; Díaz, Caridad; Uranga, Santiago; Sayes, Fadel; Vicente, Francisca; Aguiló, Nacho; Brosch, Roland; Martín, Carlos; Gonzalo-Asensio , Jesús. The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy. MOLECULAR THERAPY. NUCLEIC ACIDS. 2022. DOI: 10.1016/j.omtn.2022.02.011
- García-Morales, L.; Portillo, P. Del; Anzola, J. M.; Ares, M. A.; Helguera-Repetto, A. C.; Cerna-Cortés, J. F.; Méndez-Tenorio, A.; García, M. J.; Otal, I.; Martín, C.; Gonzalez-Y-Merchand, J. A.; Rivera-Gutiérrez, S. The lack of the TetR-like repressor gene BCG_2177c (Rv2160A) may help mycobacteria overcome intracellular redox stress and survive longer inside macrophages when surrounded by a lipid environment. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. 2022. DOI: 10.3389/fcimb.2022.907890
- Asai, Masanori; Li, Yanwen; Spiropoulos, John; Cooley, William; Everest, David J.; Kendall, Sharon L.; Martín, Carlos; Robertson, Brian D.; Langford, Paul R.; Newton, Sandra M. Galleria mellonella as an infection model for the virulent Mycobacterium tuberculosis H37Rv. VIRULENCE. 2022. DOI: 10.1080/21505594.2022.2119657
- Moreo, E.; Uranga, S.; Picó, A.; Gómez, A. B.; Nardelli-Haefliger, D.; del Fresno, C.; Murillo, I.; Puentes, E.; Rodríguez, E.; Vales-Gómez, M.; Pardo, J.; Sancho, D.; Martín, C.; Aguilo, N. Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022. DOI: 10.1136/jitc-2021-004325
- Martín, C.; Marinova, D.; Aguiló, N.; Gonzalo-Asensio, J. MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG. VACCINE. 2021. DOI: 10.1016/j.vaccine.2021.06.049
- Dijkman, K.; Aguilo, N.; Boot, C.; Hofman, S.O.; Sombroek, C.C.; Vervenne, R.A.W.; Kocken, C.H.M.; Marinova, D.; Thole, J.; Rodríguez, E.; Vierboom, M.P.M.; Haanstra, K.G.; Puentes, E.; Martin, C.; Verreck, F.A.W. Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. CELL REPORTS MEDICINE. 2021. DOI: 10.1016/j.xcrm.2020.100187
- Mata, E.; Tarancon, R.; Guerrero, C.; Moreo, E.; Moreau, F.; Uranga, S.; Gomez, A.B.; Marinova, D.; Domenech, M.; Gonzalez-Camacho, F.; Monzon, M.; Badiola, J.; Dominguez-Andres, J.; Yuste, J; Anel, A.; Peixoto, A.; Martin, C.; Aguilo, N. Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. SCIENCE IMMUNOLOGY. 2021. DOI: 10.1126/sciimmunol.abc2934
- Martinón-Torres, Federico; García-Sastre, Adolfo; Pollard, Andrew J.; Martín, Carlos; Osterhaus, Albert; Ladhani, Shamez N.; Ramilo, Octavio; Gómez Rial, Jose; Salas, Antonio; Bosch, F. Xavier; Martinón-Torres, María; Mina, Michael J.; Cherry, James. TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). HUMAN VACCINES AND IMMUNOTHERAPEUTICS. 2021. DOI: 10.1080/21645515.2021.1953351
- White, A.D.; Sibley, L.; Sarfas, C.; Morrison, A.; Gullick, J.; Clark, S.; Gleeson, F.; Mcintyre, A.; Arlehamn, C.L.; Sette, A.; Salguero, F.J.; Rayner, E.; Rodriguez, E.; Puentes, E.; Laddy, D.; Williams, A.; Dennis, M.; Martin, C.; Sharpe, S. MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. NPJ VACCINES. 2021. DOI: 10.1038/s41541-020-00262-8
- Broset, Esther; Calvet Seral, Juan; Arnal, Carmen; Uranga, Santiago; Kanno, Alex I.; Leite, Luciana C.C.; Martín, Carlos; Gonzalo-Asensio, Jesús. Engineering a new vaccine platform for heterologous antigen delivery in live-attenuated Mycobacterium tuberculosis. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL. 2021. DOI: 10.1016/j.csbj.2021.07.035
- Vierboom, M.P.M.; Dijkman, K.; Sombroek, C.C.; Hofman, S.O.; Boot, C.; Vervenne, R.A.W.; Haanstra, K.G.; Van Der Sande, M.; Van Emst, L.; Domínguez-Andrés, J.; Moorlag, S.J.C.F.M.; Kocken, C.H.M.; Thole, J.; Rodríguez, E.; Puentes, E.; Martens, J.H.A.; Van Crevel, R.; Netea, M.G.; Aguilo, N.; Martin, C.; Verreck, F.A.W. Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. CELL REPORTS MEDICINE. 2021. DOI: 10.1016/j.xcrm.2020.100185
- Tarancón, R.; Mata, E.; Uranga, S.; Gómez, A.B.; Marinova, D.; Otal, I.; Martín, C.; Aguiló, N. Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. EBIOMEDICINE. 2021. DOI: 10.1016/j.ebiom.2020.103186
- Broset, E.; Pardo-Seco, J.; Kanno, A.I.; Aguilo, N.; Dacosta, A.I.; Rivero-Calle, I.; Gonzalo-Asensio, J.; Locht, C.; Leite, L.C.C.; Martin, C.; Martinón-Torres, F. BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies. EBIOMEDICINE. 2021. DOI: 10.1016/j.ebiom.2021.103254
- Pérez, Irene; Uranga, Santiago; Sayes, Fadel; Frigui, Wafa; Samper, Sofía; Arbués, Ainhoa; Aguiló, Nacho; Brosch, Roland; Martín, Carlos; Gonzalo-Asensio, Jesús. Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential. EBIOMEDICINE. 2020. DOI: 10.1016/j.ebiom.2020.102761
- Tarancón, Raquel; Domínguez-Andrés, Jorge; Uranga, Santiago; Ferreira, Anaísa V.; Groh, Laszlo A.; Domenech, Mirian; González-Camacho, Fernando; Riksen, Niels P.; Aguilo, Nacho; Yuste, José; Martín, Carlos; Netea, Mihai G. New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLOS PATHOGENS. 2020. DOI: 10.1371/journal.ppat.1008404
- Mata, E.; Farrell, D.; Ma, R.; Uranga, S.; Gomez, A.B.; Monzon, M.; Badiola, J.; Anel, A.; Gonzalo-Asensio, J.; Martin, C.; Gordon, S.V.; Aguilo, N. Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference. PLOS PATHOGENS. 2020. DOI: 10.1371/journal.ppat.1009061
- Aguilo, N.; Uranga, S.; Mata, E.; Tarancon, R.; Gómez, A.B.; Marinova, D.; Otal, I.; Monzón, M.; Badiola, J.; Montenegro, D.; Puentes, E.; Rodríguez, E.; Vervenne, R.A.W.; Sombroek, C.C.; Verreck, F.A.W.; Martín, C. Respiratory immunization with a whole cell inactivated vaccine induces functional mucosal immunoglobulins against tuberculosis in mice and non-human primates. FRONTIERS IN MICROBIOLOGY. 2020. DOI: 10.3389/fmicb.2020.01339
- Broset, E.; Saubi, N.; Guitart, N.; Aguilo, N.; Uranga, S.; Kilpeläinen, A.; Eto, Y.; Hanke, T.; Gonzalo-Asensio, J.; Martín, C.; Joseph-Munné, J. MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT. 2019. DOI: 10.1016/j.omtm.2019.01.014
- Sanz-García, F.; Anoz-Carbonell, E.; Pérez-Herrán, E.; Martín, C.; Lucía, A.; Rodrigues, L.; Aínsa, J.A. Mycobacterial aminoglycoside acetyltransferases: a little of drug resistance, and a lot of other roles. FRONTIERS IN MICROBIOLOGY. 2019. DOI: 10.3389/fmicb.2019.00046
- Tameris, Michele; Mearns, Helen; Penn-Nicholson, Adam; Gregg, Yolande; Bilek, Nicole; Mabwe, Simbarashe; Geldenhuys, Hennie; Shenje, Justin; Luabeya, Angelique Kany K.; Murillo, Ingrid; Doce, Juana; Aguilo, Nacho; Marinova, Dessislava; Puentes, Eugenia; Rodríguez, Esteban; Gonzalo-Asensiom, Jesús; Fritzell, Bernard; Thole, Jelle; Martin, Carlos; Scriba, Thomas J.; Hatherill, Mark; Africa, Hadn; Arendsen, Denis; Botes, Natasja; Cloete, Yolundi; de Kock, Marwou; Erasmus, Margaret; Jack, Lungisa; Kafaar, Fazlin; Kalepu, Xoliswa; Khomba, Nondumiso Gloria; Kruger, Sandra; Leopeng, Thelma; Makhethe, Lebohang; Mouton, Angelique; Mulenga, Humphrey; Musvosvi, Munyaradzi; Noble, Julia; Opperman, Fajwa; Reid, Tim; Rossouw, Susan; Schreuder, Constance; Smit, Erica; Steyn, Marcia; Tyambethu, Petrus; Van Rooyen, Elma; Veldsman, Ashley; Mtbvac Clinical Trial Team. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. THE LANCET. RESPIRATORY MEDICINE. 2019. DOI: 10.1016/S2213-2600(19)30251-6
- Kaps, Iris;Ehrt, Sabine;Seeber, Silke;Schnappinger, Dirk;Martin, Carlos;Riley, Lee W.;Niederweis, Michael. Energy transfer between fluorescent proteins using a co-expression system in Mycobacterium smegmatis. GENE. 2001. DOI: 10.1016/S0378-1119(01)00712-0
Capítulos
- Los Retos de la Erradicacion de la Tuberculosis en el Siglo XXI. Gonzalo Asensio, Jesús Ángel ; Samper Blasco, Sofía ; Aínsa, José Antonio, Otal Gil, Isabel y Martín Montañés, Carlos. APLICACIÓN DE LA BIOTECNOLOGÍA EN LA CIENCIA VETERINARIA. 2012
Dirección de tesis
- Unraveling tumor-immunosuppressive mechanisms to abrogate intravenous BCG efficacy. Universidad de Zaragoza. Sobresaliente cum laude. 19/11/24
- Exploring the efficacy of MTBVAC as a desensitizing treatment against asthma. Universidad de Zaragoza. Sobresaliente cum laude. 15/03/24
- Implications of vitamin B12 in the pathogenesis of Mycobacterium tuberculosis. Universidad de Zaragoza. Sobresaliente cum laude. 18/01/24
- Estudio de rutas de vacunación en modelo murino para el uso profiláctico o terapéutico de vacunas atenuadas de tuberculosis. Universidad de Zaragoza. Sobresaliente cum laude. 26/04/23
- Fighting antimicrobial resistance in mycobacteria: development of an antivirulence screening platform and a genetic methodology to confirm drug resistance phenotypes. Universidad de Zaragoza. Sobresaliente cum laude. 17/03/23
- Use of live attenuated Mycobacteria as treatment against asthma and their ability to induce trained immunity. Universidad de Zaragoza. Sobresaliente cum laude. 13/12/19
- Construction and characterization of live attenuated vaccines in modem lieages of Mycobacterium tuberculosis based on phoP an fadD26 deletions. Universidad de Zaragoza. Sobresaliente cum laude. 04/10/19
- Study of in vivo Mycobacterium tuberculosis transcriptome in mouse model. Interaction of MTBVAC with bladder cancer tumor cells. Universidad de Zaragoza. Sobresaliente cum laude. 22/09/17
- A rationale to constuct a multivalent vaccine. Heterologous antigens expression in MTBVAC. Universidad de Zaragoza. Sobresaliente cum laude. 09/06/17
- In deep study of new tuberculosis vaccine candidates based on phoP and fadD26 mutations. Universidad de Zaragoza. Sobresaliente cum laude. 16/12/16
- Development of MTBVAC: A new live-attenuated vaccine against tuberculosis. Universidad de Zaragoza. Sobresaliente cum laude. 27/05/15
- Genotipado de Mycobacterium Tuberculosis. Diagnóstico e identificación de dos cepas altamente transmisibles y genómica de la cepa M. tuberculosis Zaragoza. Universidad de Zaragoza. Sobresaliente cum laude. 22/05/14
- PhoP regulon characterization and its implication in protein secretion in Mycobacterium tuberculosis. New vaccine construction based on phoP mutant. Universidad de Zaragoza. Sobresaliente cum laude. 09/05/14
- Construction and Characterization of a New Generation of PhoP-Based Vaccines Against Tuberculosis. Universidad de Zaragoza. Sobresaliente cum laude. 08/10/10
- Estudio intracelular del mutante phoP de Mycobacterium tuberculosis. Universidad de Zaragoza. Sobresaliente "Cum Laude". 20/11/08
- Deciphering the role of PhoP in the virulence of Mycobacterium tuberculosis. Universidad de Zaragoza. Sobresaliente "Cum Laude". 20/12/06
- Caracterización de bombas de eflujo como mecanismo de resistencia intrínseca a antibióticos en micobacterias. Universidad de Zaragoza. Sobresaliente "Cum Laude". 07/04/06
- Resistencia intrínseca a antibióticos en micobacterias: l gen aac(2')-Id, genes mutadores y bombas de eflujo. Universidad de Zaragoza. Sobresaliente "Cum Laude". 04/10/04
- Desarrollo de un sistema de Mutagenesis por transposición con gfp para el estudio de la virulencia en microbacterias y construcción de una cepa atenuada de M.tuberculosis. Universidad de Zaragoza. Sobresaliente "Cum Laude". 08/10/01
- Eflujo, un posible mecanismo de resistencia en mycobacterium tuberculosis. Universidad de Zaragoza. Sobresaliente "Cum Laude". 06/07/01
- Mecanismos de acción y Resistencias al etambutol en micobacterias. Universidad de Zaragoza. Sobresaliente "Cum Laude". 27/04/01
|